Adelphi’s disease impact and brand strategy capabilities provide global in-depth understanding of dynamics in distinct disease and decision areas.

Disease understanding and expertise are critical in ever more challenging therapeutic areas.

Our Disease Specific Programmes (DSPs), each based on up to 12,000 patients and 1000 doctors worldwide and repeated at regular intervals, constitute a ‘gold standard’ reference in the industry, providing:

• complete understanding of disease dynamics
• market definition, labelling, sizing, structure and segmentation
• key drivers for drug therapy
• unmet needs and disease impact
• detailed prescribing patterns (including dosage analysis, switching patterns, combination therapy, etc.)
• monitoring and tracking of product
• performance through regular repeat programmes
• brand mapping
• identification of market trends and changes
• impact of medico-marketing strategies
• patient motivation and behaviour.
  

Disease understanding and expertise are critical in ever more challenging therapeutic areas